

Erratum



2020; 10(5): 2402-2404. doi: 10.7150/thno.43075

Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system: Erratum

Siwen Li¹, Yuxi Liu¹, Yalan Rui¹, Liping Tang², Samuel Achilefu³, Yueqing Gu^{1,⊠}

- 1. Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, 24th Tong Jia street, Nanjing 210009, Jiangsu Province, China. Phone: 86-25-83271046; Fax: 86-25-83271046.
- 2. Department of Bioengineering, University of Texas at Arlington, Arlington, TX, USA.
- 3. Department of Radiology, School of Medicine, Washington University in St. Louis, MO, USA

 \square Corresponding author: guengineering@cpu.edu.cn

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Published: 2020.01.18

Corrected article: Theranostics 2018; 8(10): 2621-2633. doi: 10.7150/thno.24469.

In our paper [1], Figure 1 and Figure 5 should be corrected as follows.



Figure 1. The mechanism of treatment target selection and the synergistic effect of gene silencing. (A) Western blot assay after ALK siRNA, miR-301 inhibitor and miR-301 mimics transfection in H2228 cells. (B) Western blot assay after ALK siRNA transfection in A549 cells. (C) Survival of cells treated under the conditions in (A-B) determined by MTT assay. (D) Apoptosis of cells treated under the above conditions assayed by AV-PI kit. (E) Quantitative analysis of (D). Data are given as mean ± SD (n=5). *, P<0.05.





The corrected figures do not affect the original conclusions of the findings.

References

 Li S, Liu Y, Rui Y, Tang L, Achilefu S, Gu Y. Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system. Theranostics 2018; 8(10):2621-2633. doi:10.7150/thno.24469.